头孢氨苄联合甲氧苄啶-磺胺甲噁唑与单用头孢氨苄对单纯性蜂窝织炎临床治愈的影响:一项随机临床试验
该多中心、双盲、随机优效性试验在美国5个急诊科纳入500例年龄大于12岁、无伤口、无脓性分泌物或脓肿的蜂窝织炎门诊患者,比较头孢氨苄联合甲氧苄啶-磺胺甲噁唑与单用头孢氨苄的疗效。符合方案分析中,联合组临床治愈182/218(83.5%),单用组165/193(85.5%),差异为-2.0%(95%CI,-9.7%至5.7%;P=0.50),未显示联合治疗提高治愈率。
要点
- 符合方案分析中,联合组临床治愈率83.5% vs 单用组85.5%,差异-2.0%(95%CI,-9.7%至5.7%;P=0.50)。
- 改良意向治疗分析中,联合组临床治愈率76.2% vs 单用组69.0%,差异7.3%(95%CI,-1.0%至15.5%;P=0.07)。
- 两组不良事件率及7至9周次要结局(包括过夜住院、复发性皮肤感染、家庭接触者类似感染)无显著差异。
核心结论
- 在单纯性蜂窝织炎患者中,符合方案分析显示头孢氨苄联合甲氧苄啶-磺胺甲噁唑与单用头孢氨苄相比未获得更高的临床缓解率。
- 由于改良意向治疗分析结果的不精确性范围包括一个支持联合治疗的临床重要差异,可能需要进一步研究。
研究设计与样本
- 多中心、双盲、随机优效性试验,在美国5个急诊科纳入年龄大于12岁、有蜂窝织炎且无伤口、无脓性分泌物或脓肿的门诊患者。
- 2009年4月至2012年6月入组,所有参与者在入组时接受软组织超声以排除脓肿,最终随访于2012年8月。
- 共500例随机参与者,496例(99%)纳入改良意向治疗分析,411例(82.2%)纳入符合方案分析;中位年龄40岁(范围15-78岁),58.4%为男性,10.9%有糖尿病。
- 红斑中位长度和宽度分别为13.0 cm和10.0 cm。
主要发现
- 符合方案分析中,联合组临床治愈182/218(83.5%),单用组165/193(85.5%),差异-2.0%(95%CI,-9.7%至5.7%;P=0.50)。
- 改良意向治疗分析中,联合组临床治愈189/248(76.2%),单用组171/248(69.0%),差异7.3%(95%CI,-1.0%至15.5%;P=0.07)。
- 两组不良事件率及至7至9周的次要结局(包括过夜住院、复发性皮肤感染、家庭接触者类似感染)无显著差异。
关键数值与推荐
- 主要结局为符合方案人群的临床治愈,定义为随访时无以下临床失败标准:发热;红斑加重(>25%)、肿胀或压痛(第3-4天);红斑、肿胀或压痛无减轻(第8-10天);红斑、肿胀或压痛超过轻微程度(第14-21天)。
- 临床显著差异定义为大于10%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出改良意向治疗分析结果的不精确性范围包括一个支持联合治疗的临床重要差异,并认为可能需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Emergency department visits for skin infections in the United States have increased with the emergence of methicillin-resistant Staphylococcus aureus (MRSA). For cellulitis without purulent drainage, β-hemolytic streptococci are presumed to be the predominant pathogens. It is unknown if antimicrobial regimens possessing in vitro MRSA activity provide improved outcomes compared with treatments lacking MRSA activity. OBJECTIVE: To determine whether cephalexin plus trimethoprim-sulfamethoxazole yields a higher clinical cure rate of uncomplicated cellulitis than cephalexin alone. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, randomized superiority trial in 5 US emergency departments among outpatients older than 12 years with cellulitis and no wound, purulent drainage, or abscess enrolled from April 2009 through June 2012. All participants had soft tissue ultrasound performed at the time of enrollment to exclude abscess. Final follow-up was August 2012. INTERVENTIONS: Cephalexin, 500 mg 4 times daily, plus trimethoprim-sulfamethoxazole, 320 mg/1600 mg twice daily, for 7 days (n = 248 participants) or cephalexin plus placebo for 7 days (n = 248 participants). MAIN OUTCOMES AND MEASURES: The primary outcome determined a priori in the per-protocol group was clinical cure, defined as absence of these clinical failure criteria at follow-up visits: fever; increase in erythema (>25%), swelling, or tenderness (days 3-4); no decrease in erythema, swelling, or tenderness (days 8-10); and more than minimal erythema, swelling, or tenderness (days 14-21). A clinically significant difference was defined as greater than 10%. RESULTS: Among 500 randomized participants, 496 (99%) were included in the modified intention-to-treat analysis and 411 (82.2%) in the per-protocol analysis (median age, 40 years [range, 15-78 years]; 58.4% male; 10.9% had diabetes). Median length and width of erythema were 13.0 cm and 10.0 cm. In the per-protocol population, clinical cure occurred in 182 (83.5%) of 218 participants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 165 (85.5%) of 193 in the cephalexin group (difference, -2.0%; 95% CI, -9.7% to 5.7%; P = .50). In the modified intention-to-treat population, clinical cure occurred in 189 (76.2%) of 248 participants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 171 (69.0%) of 248 in the cephalexin group (difference, 7.3%; 95% CI, -1.0% to 15.5%; P = .07). Between-group adverse event rates and secondary outcomes through 7 to 9 weeks, including overnight hospitalization, recurrent skin infections, and similar infection in household contacts, did not differ significantly. CONCLUSIONS AND RELEVANCE: Among patients with uncomplicated cellulitis, the use of cephalexin plus trimethoprim-sulfamethoxazole compared to cephalexin alone did not result in higher rates of clinical resolution of cellulitis in the per-protocol analysis. However, because imprecision around the findings in the modified intention-to-treat analysis included a clinically important difference favoring cephalexin plus trimethoprim-sulfamethoxazole, further research may be needed. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00729937.
引用
- Moran GJ, Krishnadasan A, Mower WR, et al. Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis: A Randomized Clinical Trial. JAMA. 2017. PMID: 28535235. doi:10.1001/jama.2017.5653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。